Home > Insider Trading > Filing (0000899243-22-008820)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1521036	Lantheus Holdings Inc.	LNTH	In Vitro & In Vivo Diagnostic Substances (2835)	352318913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1754976	Jr. J. Robert Marshall	C/O Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica MA 01862	Cfo And Treasurer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-02-28	8,776	$0.00	135,783	No	4	A	Direct
Common Stock	Disposition	2022-03-01	8,851	$48.04	126,932	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

The transaction reported in this Form 4 reflects additional shares of common stock issued by the Company to the reporting person upon the vesting of relative Total Shareholder Return performance-based restricted stock units ("PSUs") that were previously granted and reported on a Form 4 filed on February 28, 2019. That original Form 4 reflected 100% of the target number of shares underlying the PSUs. The number of shares that actually vested under the PSUs equaled 188% of the target number of shares. Accordingly, the number of shares reported in this Form 4 reflects the difference between the number of shares that actually vested under the PSUs and the target number of shares originally reported.
The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.